Newly Diagnosed Glioblastoma Clinical Trials

27 clinical trials for Newly Diagnosed Glioblastoma across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma — RECRUITING · PHASE2
• Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII — RECRUITING · PHASE2
• Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab — RECRUITING · PHASE2
• Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma — RECRUITING · PHASE1
• New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study — RECRUITING · PHASE1
• Anterior Temporal Lobectomy in Temporal Glioblastoma — RECRUITING · PHASE3
• Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma — RECRUITING · PHASE1
• Cilengitide (EMD121974) and temozolomide with concomitant radiation therapy, followed by cilengitide and temozolomide maintenance therapy in subjects with newly diagnosed glioblastoma multiforme – a multicenter, open-label, uncontrolled Phase I/IIa study — COMPLETED · PHASE2
• BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma — NOT_YET_RECRUITING · PHASE1
• Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58) — TERMINATED · PHASE3
• Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma — COMPLETED · PHASE1
• Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma — TERMINATED · PHASE2
• A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma — COMPLETED · PHASE3
• Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma — COMPLETED · PHASE1
• Pembrolizumab for Newly Diagnosed Glioblastoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) — OTHER · PHASE2
• SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) — OTHER · PHASE2
• The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab — OTHER · PHASE4
• A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM — OTHER · PHASE1
• Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma — OTHER · PHASE2
• Phase 2 Study of CAN008 in Subjects With GBM — OTHER · PHASE2
• Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma — WITHDRAWN · PHASE1
• Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma — OTHER · PHASE2
• Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma — COMPLETED · PHASE1
• Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma — COMPLETED · PHASE3

Refine this search